Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Robert, Caroline; Ribas, Antoni; Schachter, Jacob; Arance, Ana; Grob, Jean Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S.; McNeil, Catriona M.; Lotem, Michal; Larkin, James; Lorigan, Paul; Neyns, Bart; Blank, Christian U.; Petrella, Teresa M.; Hamid, Omid; Su, Shu; Krepler, Clemens; Ibrahim, Nageatte; Long, Georgina V.

doi:10.1016/s1470-2045(19)30388-2

Cited by 825 publications

(746 citation statements)

References 17 publications

Supporting

Mentioning

696

Contrasting

Unclassified

Order By: Relevance

“…According to Larkin J. et al (2019), a sustained long-term overall survival at five years was obtained with immunotherapeutic agents in the following descending order: nivolumab plus ipilimumab (more than 60.0 months), nivolumab alone (36.9 months), ipilimumab alone (19.9 months) [23]. In the KEYNOTE-006 trial, pembrolizumab showed superiority over ipilimumab after almost five years of follow-up with respect to the median overall survival (32.7 months versus 15.9 months) and the median progression-free survival (8.4 months versus 3.4 months) [24].…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

“…The most frequently encountered irAEs are dermatological (vitiligo-like leukoderma, lichenoid dermatitis, psoriasiform dermatitis, or even potentially life-threatening conditions such as Stevens Johnson Syndrome), diarrhea/colitis, hepatitis, pneumonitis, and endocrine toxicities (requiring hormonal supplementation). In the KEYNOTE-006 trial, patients treated with pembrolizumab, severe grade 3-4 treatment-related adverse events occurred in 96 (17%) of 555 patients in the combined pembrolizumab groups and in 50 (20%) of 256 patients in the ipilimumab group [24].…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Nanosystems for Improved Targeted Therapies in Melanoma

Beiu

Giurcăneanu

Grumezescu

et al. 2020

JCM

View full text Add to dashboard Cite

Melanoma is one of the most aggressive forms of skin cancer, with limited therapeutic options. Since its incidence has been rapidly rising in recent years, the study of new targeted therapeutic strategies has increased. The implication of nanoscience in the development of alternative targeted therapies for melanoma has multiple benefits and could significantly improve the outcome of melanoma patients. In this paper, we review the most recent progress in the field of targeted therapies, emphasizing the impact of nanoscale materials on the targeting and controlled release of anti-tumor drugs. The applications of nanomedicine in the management of melanoma are extensive and refer to sentinel lymph node mapping, chemotherapy, and RNA interference; each of these applications harboring the potential to develop efficient and personalized diagnostic techniques and therapies. Further research, especially in clinical trials, is needed to establish whether fighting melanoma on the nanoscale level represents the key to reaching a critical inflection point in mankind’s battle with metastatic melanoma.

show abstract

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Nanosystems for Improved Targeted Therapies in Melanoma

Beiu

Giurcăneanu

Grumezescu

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Ipilimumab, an antibody aiming CTLA-4 (cytotoxic T lymphocyte associated antigen 4), was the first immunotherapy to increase overall survival (OS) [1]. Antibodies directed against PD-1 (programmed cell death 1) offered higher efficacy [2,3]. In KEYNOTE-006 trial, median OS was 32.7 months with pembrolizumab and 15.9 months with ipilimumab (hazard ratio (HR) 0·73; p = 0·00049) [2].…”

mentioning

confidence: 99%

Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?

Hindié

2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…Some patients achieved long-term survival with ipilimumab but the response rates were still relatively low, approximately 20%. Antiprogrammed death-1 (anti-PD-1) treatment has shown superiority compared to anti-CTLA-4 in advanced melanoma [4,5]. For example, among patients receiving pembrolizumab as first line therapy, the median OS was 38.7 versus 17.1 months for ipilimumab (hazard ratio (HR) ¼ 0.73, p ¼ .0036) [4].…”

mentioning

confidence: 99%

“…Antiprogrammed death-1 (anti-PD-1) treatment has shown superiority compared to anti-CTLA-4 in advanced melanoma [4,5]. For example, among patients receiving pembrolizumab as first line therapy, the median OS was 38.7 versus 17.1 months for ipilimumab (hazard ratio (HR) ¼ 0.73, p ¼ .0036) [4]. By combining anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab), objective response rates (ORRs) and OS have increased further [5].…”

mentioning

confidence: 99%